Literature DB >> 17440082

Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice.

Yong Wang1, Archana Thakur, Yuan Sun, Jack Wu, Hector Biliran, Aliccia Bollig, D Joshua Liao.   

Abstract

Cyclin D1 is one of the most commonly overexpressed oncogenes in breast cancer; yet, it is not clear whether cyclin D1 alone is capable of causing malignant transformation of mammary epithelial cells. Here, we show that ectopic expression of cyclin D1 in benign mouse mammary epithelial cells promotes cell proliferation, anchorage-independent growth in soft agar, and tumorigenesis in severe combined immunodeficient mice. To address the possible interaction of cyclin D1 and c-myc in malignant transformation, we used cyclin D1/c-myc dual-expressing clones, which displayed more aggressive and invasive phenotype than cyclin D1-expressing clones. These data provide evidence that overexpression of cyclin D1 or coexpression with c-myc could cause invasive malignant transformation of benign mouse mammary epithelial cells. Furthermore, microarray analysis of cyclin D1 and cyclin D1/c-myc clones showed that these two tumor-producing clones might use distinct invasive pathways. In summary, overexpression of cyclin D1 may commit mammary epithelia to a tumor-prone phenotype in which cooperation with other genes, such as synergy with c-myc, may lead to a more aggressive phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440082     DOI: 10.1158/0008-5472.CAN-06-4000

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

Review 1.  Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Authors:  Chenguang Wang; Michael P Lisanti; D Joshua Liao
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

Review 2.  MEK5/ERK5 pathway: the first fifteen years.

Authors:  Barbara A Drew; Matthew E Burow; Barbara S Beckman
Journal:  Biochim Biophys Acta       Date:  2011-10-13

3.  Cyclin-dependent kinase 4 may be expressed as multiple proteins and have functions that are independent of binding to CCND and RB and occur at the S and G 2/M phases of the cell cycle.

Authors:  Yuan Sun; Xiaomin Lou; Min Yang; Chengfu Yuan; Ling Ma; Bing-Kun Xie; Jian-Min Wu; Wei Yang; Steven Xj Shen; Ningzhi Xu; D Joshua Liao
Journal:  Cell Cycle       Date:  2013-09-24       Impact factor: 4.534

4.  Identification of the cyclin D1b mRNA variant in mouse.

Authors:  Jack Wu; Si-hung Wu; Aliccia Bollig; Archana Thakur; D Joshua Liao
Journal:  Mol Biol Rep       Date:  2008-04-30       Impact factor: 2.316

5.  Basic anatomy and tumor biology of the RPS6KA6 gene that encodes the p90 ribosomal S6 kinase-4.

Authors:  Y Sun; S Cao; M Yang; S Wu; Z Wang; X Lin; X Song; D J Liao
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

6.  In silico analysis of combinatorial microRNA activity reveals target genes and pathways associated with breast cancer metastasis.

Authors:  Alan A Dombkowski; Zakia Sultana; Douglas B Craig; Hasan Jamil
Journal:  Cancer Inform       Date:  2011-02-17

7.  Complex alternative splicing of the smarca2 gene suggests the importance of smarca2-B variants.

Authors:  Min Yang; Yuan Sun; Ling Ma; Chenguang Wang; Jian-Min Wu; Anding Bi; D Joshua Liao
Journal:  J Cancer       Date:  2011-07-06       Impact factor: 4.207

8.  Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome".

Authors:  Martina Galatola; Lorella Paparo; Francesca Duraturo; Mimmo Turano; Giovanni Battista Rossi; Paola Izzo; Marina De Rosa
Journal:  BMC Med Genet       Date:  2012-04-20       Impact factor: 2.103

9.  Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120 catenin activity.

Authors:  Antonis Kourtidis; Siu P Ngok; Pamela Pulimeno; Ryan W Feathers; Lomeli R Carpio; Tiffany R Baker; Jennifer M Carr; Irene K Yan; Sahra Borges; Edith A Perez; Peter Storz; John A Copland; Tushar Patel; E Aubrey Thompson; Sandra Citi; Panos Z Anastasiadis
Journal:  Nat Cell Biol       Date:  2015-08-24       Impact factor: 28.824

10.  Pseudogenes as weaknesses of ACTB (Actb) and GAPDH (Gapdh) used as reference genes in reverse transcription and polymerase chain reactions.

Authors:  Yuan Sun; Yan Li; Dianzhong Luo; D Joshua Liao
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.